Ligand Pharmaceuticals Aktie [WKN DE: 895777 / ISIN: US53220K2078]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Ligand Pharmaceuticals Inc

24.08.22		Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (Businesswire)
08.08.22		Ligand Reports Second Quarter 2022 Financial Results (Businesswire)
02.08.22		Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Businesswire)
22.07.22		Ligand to Report Second Quarter Financial Results on August 8 (Businesswire)
29.06.22		Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors (Businesswire)
04.05.22		Ligand Reports First Quarter 2022 Financial Results (Businesswire)
19.04.22		Ligand to Report First Quarter Financial Results on May 4 (Businesswire)
08.04.22		Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
23.03.22		Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II (Businesswire)
17.02.22		Ligand Reports Fourth Quarter and Full Year 2021 Financial Results (Businesswire)
09.02.22		Ligand to Report Fourth Quarter Financial Results on February 17 (Businesswire)
22.12.21		Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy (Businesswire)
21.12.21		Ligand and GSK Expand Global Collaboration and License Agreement (Businesswire)
03.05.21		Ligand Reports First Quarter 2021 Financial Results (Businesswire)
22.04.21		Ligand to Report First Quarter Financial Results on May 3, 2021 (Businesswire)
03.02.21		Ligand Reports Fourth Quarter and Full Year 2020 Financial Results (Businesswire)
02.02.21		Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis (Businesswire)
20.01.21		Ligand’s Fourth Quarter Financial Results to be Reported February 3rd (Businesswire)
13.01.21		Ligand Receives Milestone Payment from Merck (Businesswire)
21.12.20		Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders (Businesswire)
23.11.20		Ligand Announces Clinical and Regulatory Progress by Multiple Partners with OmniAb® Antibodies (Businesswire)
06.11.20		Ligand’s Partner Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ for the Treatment of Status Epilepticus in Adult and Pediatric Patients (Businesswire)
30.10.20		Ligand Reports Third Quarter 2020 Financial Results (Businesswire)
23.10.20		Ligand’s Captisol Technology Plays Key Role in the Manufacture of Gilead’s Veklury, the First FDA-Approved COVID-19 Treatment (Businesswire)
20.10.20		Ligand Provides Highlights from Today’s Investor Day Event (Businesswire)
19.10.20		Ligand’s Third Quarter Financial Results to be Reported October 30th (Businesswire)
12.10.20		Ligand to Divest Vernalis Research Operations (Businesswire)
02.10.20		Ligand to Host Virtual Investor Day on October 20th (Businesswire)
01.10.20		Ligand Completes Acquisition of Pfenex Inc. (Businesswire)
30.09.20		Ligand Announces Expiration of Tender Offer for Shares of Pfenex Inc. (Businesswire)
23.09.20		Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million (Businesswire)
10.09.20		Ligand Expands OmniAb® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences (Businesswire)
01.09.20		Ligand Pharmaceuticals Management to Present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference (Businesswire)
31.08.20		Ligand Commences Previously Announced Cash Tender Offer to Acquire Pfenex Inc. (Businesswire)
25.08.20		Ligand OmniAb® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis (Businesswire)
10.08.20		Ligand to Acquire Pfenex Inc. (Businesswire)
03.08.20		Ligand Reports Second Quarter 2020 Financial Results (Businesswire)
16.07.20		Ligand’s Second Quarter Financial Results to be Reported August 3rd (Businesswire)
15.06.20		Ligand Announces an Expansion of Vernalis Collaboration with Servier for Research on Novel Oncology Targets (Businesswire)
01.06.20		Ligand CEO Issues Letter to Captisol Customers (Businesswire)
06.05.20		Ligand Reports First Quarter 2020 Financial Results (Businesswire)
22.04.20		Ligand’s First Quarter Financial Results to be Reported May 6th (Businesswire)
02.04.20		Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies (Businesswire)
06.02.20		Ligand Reports Fourth Quarter and Full Year 2019 Financial Results (Businesswire)
03.02.20		Ligand's Technologies Support and Enable Potential Coronavirus Treatments (Businesswire)
13.01.20		Ligand Enters into OmniAb® Platform License Agreement with Pandion Therapeutics (Businesswire)
09.01.20		Ligand to Report 2019 Fourth Quarter and Full Year Financial Results on February 6th (Businesswire)
23.12.19		Two Ligand Pharmaceuticals Board Members Recognized as 2019 Most Influential Corporate Directors by WomenInc. Magazine (Businesswire)
02.12.19		Ligand Enters into Worldwide OmniAb® Platform License Agreement with Sanofi (Businesswire)
12.11.19		Ligand Pharmaceuticals Ranked in Deloitte’s 2019 Technology Fast 500™ (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

XRP mit Rekordrally: Ripple-CEO glaubt an US-Krypto-Boom unter Trump

Pierer-Aktie letztlich zweistellig höher: KTM ist insolvent - Antrag auf Sanierung in Eigenverwaltung

Ripple steigt deutlich: Neues ATH noch in 2024?

VW-Aktie unter Druck: Flächendeckender Streik bei Volkswagen - Tausende Jobs in Österreich abhänging

KTM-Insolvenz: Betriebsversammlungen gestartet

Ripple im Höhenflug: XRP steigt um 30 Prozent und erreicht Top-3 der Kryptowährungen

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	04.12.2024 22:24
Kaufwert:	EUR
	Hinzufügen Speichern